AMNOG process Archives — Page 7 of 12 — German Market Access

G-BA decisons from 20July 2023

Here are the G-BA decisions from the G-BA meeting held on 20 July 2023 on the early benefit assessments of Enhertu, Imbruvica,

Here are the G-BA decisions from the G-BA meeting held on 12 May 2023 on the early benefit assessments of Tezpire, Adtralza

Here are the G-BA decisions from the G-BA meeting held on 20 April 2023 on the early benefit assessments of Ultomiris, Genvoya,

On Friday, 21 Oct 2022, the German House of Representatives has now finalized the law on the financial stabilization of statutory health

Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,